UCB has gained European approval to market Cimzia to treat rheumatoid arthritis, a decision that followed the FDA's approval in May. The decision, which was widely expected, allows UCB a much broader market for the TNF therapy, which is the fourth to hit the market behind Enbrel, Remicade and Humira. UCB is collaborating with Nektar Therapeutics, which gains royalties on sales. Report [1]
Links:
[1] http://www.reuters.com/article/marketsNews/idUSLQ59057320090626